Cargando…

Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model

BACKGROUND: Ursodeoxycholic acid (UDCA), statins, and ezetimibe (EZE) have demonstrated beneficial effects against non-alcoholic fatty liver disease (NAFLD). We investigated the efficacy of the combination of UDCA and the mix of rosuvastatin (RSV)/EZE in the treatment of NAFLD. METHODS: NAFLD mouse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Sang Hyun, Lee, Da Hyun, Lee, Yu Seol, Cho, Kyung Joo, Park, Hye Jung, Lee, Hye Won, Kim, Beom Kyung, Park, Jun Yong, Kim, Do Young, Ahn, Sang Hoon, Bae, Soo Han, Kim, Seung Up
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379373/ https://www.ncbi.nlm.nih.gov/pubmed/35982712 http://dx.doi.org/10.1093/gastro/goac037

Ejemplares similares

Effect of fixed‐dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS‐ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe)
por: Kim, Kyung‐Jin, et al.
Publicado: (2016)

Pharmacokinetics of fixed-dose combination of rosuvastatin 20 mg and ezetimibe 10 mg compared to concurrent administration of individual tablets in healthy Korean subjects
por: Hwang, Inyoung, et al.
Publicado: (2018)

The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study
por: Moon, Jun Sung, et al.
Publicado: (2023)

Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects
por: Kim, Chang Hee, et al.
Publicado: (2017)

Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
por: Lee, Jae Seung, et al.
Publicado: (2021)

Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial
por: Hong, Keun-Sik, et al.
Publicado: (2023)

Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study
por: Lee, Jiwoo, et al.
Publicado: (2020)

Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma
por: Seo, Sang Hyun, et al.
Publicado: (2023)

Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy
por: Chang, Jin Won, et al.
Publicado: (2021)

Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease
por: Chun, Ho Soo, et al.
Publicado: (2021)

Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease
por: Kim, Yuna, et al.
Publicado: (2022)

A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol
por: Niedzielski, Mateusz, et al.
Publicado: (2021)

The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia
por: Rhee, Moo-Yong, et al.
Publicado: (2017)

Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2019)

Effect of High-Intensity Rosuvastatin vs. Combination of Low-Intensity Rosuvastatin and Ezetimibe on HbA1c Levels in Patients without Diabetes: A Randomized IDEAL Trial
por: Choe, Jeongcheon, et al.
Publicado: (2023)

External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
por: Lee, Jae Seung, et al.
Publicado: (2022)

Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
por: Lee, Jae Seung, et al.
Publicado: (2021)

Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights
por: Chilbert, Maya R, et al.
Publicado: (2022)

Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation
por: Yun, Byung-Yoon, et al.
Publicado: (2020)

Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization
por: Kim, Yuna, et al.
Publicado: (2021)

Efficacy and Safety of Coadministered Ezetimibe–Rosuvastatin plus Telmisartan in South Korean Patients with Dyslipidemia and Hypertension: A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase III Trial
por: Song, Zhao-Yan, et al.
Publicado: (2023)

The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
por: Lee, Hye Won, et al.
Publicado: (2021)

Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus
por: Hwang, You-Cheol, et al.
Publicado: (2019)

Clinical characteristics and prognosis of Korean patients with hepatocellular carcinoma with respect to etiology
por: Jang, Wonjoon, et al.
Publicado: (2022)

Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
por: Lee, Jae Seung, et al.
Publicado: (2022)

Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction
por: Ren, Yizhi, et al.
Publicado: (2017)

A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia
por: Kim, Min Chul, et al.
Publicado: (2023)

Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease
por: Han, Eugene, et al.
Publicado: (2022)

Pharmacokinetic interactions between telmisartan/amlodipine and rosuvastatin after multiple oral administrations in healthy Korean male subjects
por: Moon, Seol Ju, et al.
Publicado: (2019)

Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice
por: Kim, Ja Kyung, et al.
Publicado: (2014)

Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
por: Kim, David Sooik, et al.
Publicado: (2021)

Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
por: Lee, Hye Won, et al.
Publicado: (2020)

Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria
por: Lee, Jae Seung, et al.
Publicado: (2022)

Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals
por: Lee, Hye Won, et al.
Publicado: (2019)

Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals
por: Lee, Hye Won, et al.
Publicado: (2019)

Author Correction: Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals
por: Lee, Hye Won, et al.
Publicado: (2019)

Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma
por: Lee, Sang Hoon, et al.
Publicado: (2015)

Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, in vitro and in vivo
por: Cho, Yongin, et al.
Publicado: (2020)

Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects
por: Kang, Woo Youl, et al.
Publicado: (2018)

Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase
por: Lee, Hye Won, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m0i9e8j6p1mgh113cmforjrkk7